These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12172461)

  • 1. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux: a new antithrombotic agent.
    Cheng JW
    Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
    Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
    Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
    Nijkeuter M; Huisman MV
    Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
    N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
    Zhang Y; Zhang M; Tan L; Pan N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
    Lobo BL
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):66S-72S. PubMed ID: 15317401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.